GE HealthCare targets dense breast screening with two new ultrasound tools

Mammography misses roughly one-third of cancers in women with dense breasts. That's a well-documented problem, and one that GE HealthCare is now addressing with two new additions to its breast imaging portfolio: the Invenia ABUS Prime automated ultrasound system and ABUS StreamVue, a browser-based exam viewer that recently received both FDA 510(k) clearance and CE Marking.

Dense breast tissue affects 40% of women and raises their risk of developing breast cancer by four to six times. The clinical case for supplemental ultrasound screening is strong, and demand is growing. BeSound, a breast imaging clinic in Los Angeles, is among the first U.S. sites to install Invenia ABUS Prime, with plans to extend services through a mobile screening unit.

How does it work?

Invenia ABUS Prime is an automated 3D ultrasound system built for high-volume breast imaging programs. It runs on GE's cSound imageformer with AI tools, including Scan Quality Assessment and Auto Nipple Detection, powered by the Verisound AI platform. A Fast Scan feature cuts scan time by up to 40% compared to the previous generation. AI-assisted reading, powered by QVCAD, has shown a 33% reduction in reading time and up to 93% sensitivity for lesion detection in published studies.

ABUS StreamVue, developed with imaging technology company Candelis, is a zero-footprint viewer that runs in any browser. Key features include:

• Remote ABUS exam review across enterprise networks
• Standardized image presentation for multi-site consistency
• Flexible licensing to simplify IT deployment and maintenance
• No local installation required

Why does it matter?

The combination of a standardized acquisition system and a remote reading platform directly addresses one of the biggest operational challenges in breast imaging: scaling quality screening across multiple sites without adding complexity. For health networks running high volumes, that matters as much as the clinical performance.

The context

Across the GCC, breast cancer is among the most common cancers in women, and national screening programs in Saudi Arabia and the UAE are actively expanding access. As regional health systems invest in AI-enabled diagnostics and multi-site imaging infrastructure under frameworks like Vision 2030 and the UAE's National Health Strategy, tools that combine clinical accuracy with operational flexibility are exactly what procurement teams are evaluating. GE HealthCare's dual launch positions the company squarely in that conversation.